Publicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (83)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion (American Journal of Clinical Dermatology, (2023), 24, 1, (5-14), 10.1007/s40257-022-00732-w)

    American Journal of Clinical Dermatology

  3. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  4. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

  5. Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

    BMC Cancer, Vol. 23, Núm. 1

  6. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688

  7. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  8. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  9. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion

    American Journal of Clinical Dermatology, Vol. 24, Núm. 1, pp. 5-14

  10. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

2022

  1. Code of practice needed for samples donated by trial participants

    The Lancet Oncology

  2. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427

  3. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors

    Journal of Neuroendocrinology, Vol. 34, Núm. 3

  4. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

  5. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

    Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48

  6. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  7. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554

  8. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311

  9. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

    ESMO Open, Vol. 7, Núm. 2